Pfizer’s Bosulif Too Expensive And Lacks Data, Says NICE
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has rejected Bosulif for leukemia principally on cost grounds, but also due to a lack of comprehensive long-term data, which is also being sought by the EMA.
You may also be interested in...
European Notebook: U.S. Investors Tap Into Europe; New U.K. Pricing Scheme; Pfizer Dismayed By German Payers
Europe's IPO window remains closed but the region still attracts U.S. investors; drug spending set to decline in Greece and Spain in 2014; Pfizer takes Bosulif off the German market because agreement on price unlikely with health insurers; no room for value-based pricing in the U.K.; European Parliament clears €80 billion in research funding under Horizon 2020.
Novartis Triumphs At EMA With Jetrea, But Merck Has Suspension of Three Merck Products Confirmed
The EMA has given the nod to Novartis subsidiary Alcon’s vitreomacular traction drug Jetrea and agreed to an indication extension for its Ilaris product to treat gouty arthritis. EMA’s Committee for Medicinal Products for Human Use also confirmed a recommendation to suspend the marketing authorizations of three Merck Sharp & Dohme products used to treat adults with dyslipidemia.
U.K. Provides £50 Million Extra For Cancer Drugs
Extra funds made available in the U.K. for anti-cancers turned down by NICE, with a £200 million fund to be set up next year.